Ignite Creation Date:
2024-05-05 @ 11:49 PM
Last Modification Date:
2024-10-26 @ 10:40 AM
Study NCT ID:
NCT01425203
Status:
COMPLETED
Last Update Posted:
2021-02-08
First Post:
2011-08-26
Brief Title:
The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 P08160
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
Safety and Efficacy of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for Treatment of Chronic Hepatitis C Genotype 1 in Russia Previously Untreated Patients and Patients Who Failed Prior Treatment With Pegylated-Interferon Plus Ribavirin
Status:
COMPLETED
Status Verified Date:
2021-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether Boceprevir BOC SCH 503034 MK-3034 in combination with Peginterferon Alfa 2-b PEG plus Ribavirin RBV PEGRBVPR is effective in the treatment of chronic hepatitis C CHC genotype 1 among the Russian population The primary hypothesis is that the percentage of participants achieving sustained virologic response in the BOC PR group is superior to that in the Placebo PBO PR group
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MK-3034-046 | OTHER | Merck | None |